ArticleNews reportPHN-05132026-11-01 17:23 CT

Hypera stock: Semavy becomes top-selling drug as Q3 profit rises - ad-hoc-news.de

Source · Google News

TLDR

According to the report, Hypera’s semaglutide-based Semavy became its top-selling product after launching in September, with 93,000 units sold that month. Hypera reported third-quarter adjusted net income of BRL 527 million, up 16%, while higher launch-related spending pressured margins.

01—Key points

01Hypera reported revenue of BRL 2.4 billion, up 9.4% year over year, and said Semavy helped offset declining flu-medication sales.
02Continuing-operations EBITDA rose 3.4%, but its margin fell 1.9 percentage points to 32.1%; Hypera cited higher marketing and sales expenses.
03The report says Semavy is initially indicated for diabetes treatment; September sales were expected to double in October.

Why it matters Editorial

The launch provides an early measure of semaglutide’s commercial contribution to Hypera while highlighting the associated marketing costs.

Read the original at Google News↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.